Related Experiment Video
Updated: Jun 12, 2026
09:47
DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
Alzheimer's disease: advances in basic research and therapies
1Department of Brain & Cognitive Sciences and Clinical Research Center, E10-003, Massachusetts Institute of Technology, Cambridge, MA 02139, U.S.A.
Neurochemistry International
|May 27, 2010
Summary
Scientists convened to discuss Alzheimer's disease research, exploring genetics, neuroimaging, and therapies. Advances in understanding memory disorders and potential treatments were highlighted.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Alzheimer's disease is a progressive neurodegenerative disorder impacting memory and cognitive functions.
- Aging populations worldwide face increasing prevalence of memory disorders.
- Effective therapies for Alzheimer's disease remain a critical unmet medical need.
Purpose of the Study:
- To review and discuss recent advances in basic research and therapeutic strategies for Alzheimer's disease.
- To foster collaboration among international experts in memory disorders.
- To identify key challenges and future directions in Alzheimer's disease research.
Main Methods:
- The conference brought together 121 scientists from 14 nations.
- Research approaches included genetics, neuroimaging, neuropsychology, neurochemistry, neuropathology, and animal studies.
- Discussions focused on fundamental science and clinical applications.
Main Results:
- A comprehensive overview of current research trends in Alzheimer's disease was presented.
- Key findings from diverse scientific disciplines were shared.
- Progress in understanding the underlying mechanisms of memory disorders was discussed.
Conclusions:
- The conference highlighted the multidisciplinary nature of Alzheimer's disease research.
- Advances in basic science offer promising avenues for future therapeutic development.
- Continued international collaboration is essential for combating memory disorders associated with aging.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...